In human medicine, the carbonic anhydrase(CA) inhibitor acetazolamide is used to treat irregular breathing disorders. Previously, we demonstrated in the rabbit that this substance stabilized closed-loop gain properties of the respiratory control system, but concomitantly weakened respiratory muscles. Among others, the highly diffusible CA-inhibitor methazolamide differs from acetazolamide in that it fails to activate Ca 2+ -dependent potassium channels in skeletal muscles. Therefore, we aimed to find out, whether or not methazolamide may exert attenuating adverse effects on respiratory muscle performance as acetazolamide. In anaesthetized spontaneously breathing rabbits (N=7), we measured simultaneously the CO 2 responses of tidal phrenic nerve activity, tidal transpulmonary pressure changes and tidal volume before and after intravenous application of methazolamide at two mean (±SEM) cumulative doses of 3.5 ±0.1 and 20.8 ±0. In cardio-respiratory medicine, the carbonic anhydrase (CA) inhibitor acetazolamide (ACTZ) is known for beneficial effects in patients with central sleep apnea (12, 41). Furthermore, it is used to improve blood gases in obstructive lung disease and to restore acid-base values in metabolic alkalosis, reviewed by (30). ACTZ is also widely used against Acute Mountain Sickness (1, 18, 29), most likely because it is able to reduce hypoxic pulmonary vasoconstriction (HPV) and to prevent high altitude pulmonary edema (2, 32). However, there is growing evidence from recent studies in different species that ACTZ may prevent hypoxic pulmonary vasoconstriction entirely independent of carbonic anhydrase inhibition (11) and rather may diminish the hypoxia-induced rise in intracellular Ca 2+ in pulmonary arterial smooth muscle cells (25).
Introduction
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were continuously recorded (Chart recorder MT95K2, Astro-Med, Warwick, RI).
Arterial blood gases and pH were measured at (the controlled body temperature of) 38° by conventional equipment (ABL 5, Radiometer, Copenhagen, Denmark).). Standard bicarbonate and base excess (BE) were estimated directly from pH of samples equilibrated with two (4% and 8% CO 2 in O 2 ) precise gas mixtures (BMS2 Mk2 blood microsystem, Radiometer, Copenhagen, Denmark; Precision gas-mixing pump, Wösthoff, Bochum, Germany). Concentrations of hemoglobin and lactate were determined photometrically (Spectrophotometer: Hitachi-100-10, Tokyo, Japan, with standard test combinations from Merck, Darmstadt and Labor+Technik Eberhard Lehmann, Berlin, Germany).
Experimental protocol. Throughout the experiment, the animals inhaled oxygenenriched air (F I O 2 =0.37). We measured respiratory variables under control conditions at zero inspired CO 2 and at four elevated levels of about 3, 4, 6 and 8%, yielding arterial PCO 2 values between 5.48 ±0.22 and 7.85 ±0.19 kPa. These CO 2 steps were repeated twice, first after intravenous low-dose infusion (0.5 ml/min for 10 min) of methazolamide up to 3.5 ±0.1 mg·kg -1 , and second after high-dose infusion (2.5 ml/min for 10 min) up to 20.8 ±0.4 mg·kg -1 .
The substance was dissolved in saline plus 1N NaOH plus 1N HCl, adjusted to pH 7. 35-7.45 (solute concentration: 2.14 ±0.10 mg·ml -1 ). The total period of measurements took about 5
hours (322 ± 8 min).
Data processing and statistical Analysis. Respiratory rate (f R =60/T I +T E ), pulmonary ventilation ( V =V T ·f R ) and tidal respiratory work (V T ·ΔP TP ) were calculated. The integrated tidal phrenic amplitude (IPNA) was normalized to the maximum arbitrary value achieved in each animal (14, 15). Unless otherwise indicated, data are means ± SEM. Group mean values resulting from application of methazolamide were compared with those under control conditions by paired-samples t-tests. In each animal, linear regression analysis was performed for various relationships between V T and ΔP TP and IPNA during CO 2 -inhalation. The resulting individual slopes (and intercepts) likewise underwent paired t-tests to detect significant differences between experimental conditions. Differences were regarded as significant with P D ≤0.05. Statistical analysis was performed by SPSS 11.0 for Windows (SPSS, Chicago, IL).
Results
General effects of methazolamide on pulmonary ventilation and related variables. Table 1 summarizes the effects of methazolamide (MTZ) on eucapnic base-line ventilation, gas exchange and acid-base conditions. At low dose, the agent increased ventilation and tidal volume by about 50% and 45%, respectively, with no change in respiratory rate, and lowered the mean end tidal PCO 2 by 1.73 kPa. At high dose, the relative rises in ventilation and tidal volume were in the range of 165% and 112 %, respectively, along with about 3.6 kPa reduction in end tidal P CO 2 . Upon low-dose application, the arterial to end tidal CO 2 difference (D(aet)CO 2 ) rose only transiently and reached the control range again (0.15 ±0.12 kPa) after about one hour. However, with high doses, the increases in D(a-et)CO 2 were large (2.64 ±0.14 and 1.64 ±0.15 kPa; Fig. 1 ) and persisted for the duration of the trial. Whereas the base excess (BE) remained stable for more than two hours during the control phase, MTZ reduced BE values in a dose-dependent manner by up to 8.3 mmol·l -1 , without significant change in blood lactate concentration. The substance did not exert any effect on mean arterial blood pressure.
Likewise, there was no significant effect of MTZ on the dynamic lung compliance within the investigated range of respiratory drive: the mean V T -ΔP TP -relationship showed a non-linear characteristic that remained unaffected by MTZ at either dosage (Fig. 2 ). performance in response to a given neural phrenic drive, namely by more than 50% (15).
Since the average control-line in the ACTZ study is steeper than that in the present study on MTZ, it is important to note that the different effects of both substances were independent of individual control slopes.
Discussion
The present study explores respiratory effects of methazolamide (MTZ) in spontaneously breathing rabbits, making use of the same protocol as previously (14, 15) to study effects of acetazolamide (ACTZ). Thereby, we assessed respiratory neuro-mechanical coupling by simultaneous recordings of phrenic nerve activity, tidal volume and transpulmonary pressure.
The main result of this study was that neither low nor high doses of the more lipophilic CA inhibitor MTZ significantly impaired the transmission of a CO 2 -induced rise in phrenic nerve activity into adequate changes of volume, pressure or respiratory work. These results suggest that respiratory muscles are able to function normally independent of local CA activity. In retrospect, it follows that the impairment of respiratory neuromuscular coupling observed previously with low and high dose ACTZ likewise may have been largely independent of CA inhibition.
Effects of MTZ on pulmonary ventilation, gas-exchange and acid-base conditions. Similar
to ACTZ in clinical use, MTZ at a low cumulative dose of 3.5 mg·kg8 transient arterial-to-end tidal PCO 2 gradient that disappeared after 60 min, indicating that red cell carbonic anhydrase (CA) was not yet completely inhibited. Higher cumulative doses of MTZ up to ~20 mg·kg -1 caused a large and persistent arterial-to-end-tidal PCO 2 gradient ( Fig.   1 ), which can be ascribed to complete red cell CA inhibition. Although this initially will cause CO 2 /H 2 CO 3 disequilibrium in the blood after lung passage, samples obtained from the femoral artery had time to achieve high PCO 2 values despite the delayed chemical equilibrium ( Table 1 ).
In much the same way as ACTZ, both low and high dose MTZ increased steady state ventilation. However, MTZ elicited more pronounced respiratory responses at much lower plasma concentrations than those required for ACTZ. Since MTZ and ACTZ have about equal affinities for CA isoforms II and IV, the higher efficacy of MTZ to drive pulmonary ventilation may be because this highly lipophilic sulfonamide more easily permeates through cell membranes. Therefore MTZ is distributed rather rapidly and even in many tissues including brain cells, where it accumulates about 4-fold compared to ACTZ (20). Thus, besides the complete inhibition of red cell CA, effective blockade of membrane-bound CA at the luminal surface of brain capillary endothelium will impair removal of CO 2 from brain tissue and thus add to the chemical drive from central chemoreceptors (29, 33) . The latter explanation also applies to low-dose MTZ as smaller amounts of this highly diffusible inhibitor may effectively block the easily accessible brain endothelial CA as well and cause some degree of tissue acidosis (29) .
Apart from respiratory (brain) tissue acidosis, we cannot exclude additional driving forces on ventilation by the considerable dose-dependent non-respiratory acid accumulation. In humans, metabolic acidosis normally leads to an increase in ventilation, for which the peripheral chemoreceptors may be responsible (26, 27, 30, 36 ] in pulmonary artery smooth muscle cells (11, 25). Thus, at least in the pulmonary vascular bed and under hypoxic conditions a vasodilator effect independent of CA inhibition seems to be lacking for MTZ. It needs further investigation to decide, whether this observation also extends to other regions of the circulatory system and thus may explain why MTZ does not induce general systemic hypotension.
Effect of MTZ on dynamic compliance. There was no significant effect of low-or highdose MTZ on the dynamic lung compliance within the investigated range of respiratory drive.
This agrees with our earlier finding that also ACTZ at neither dosage did significantly affect the relationship between V T and ΔP TP (14, 15) and is speaking against any role of carbonic anhydrase for the adjustment of bronchial smooth muscular tone. The fact that MTZ has no adverse effect on lung stiffness is important for assessing the transmission of phrenic nerve activity into respiratory muscle performance from volume and pressure responses (see below).
No attenuating effect of MTZ on respiratory muscle performance. Low-dose MTZ did not affect the transmission of phrenic neuronal drive into respiratory volume and pressure res-ponses, thus bearing a striking difference to ACTZ that at a comparable level of CA inhibition, already accomplished respiratory muscle weakening by more than two thirds (14, 15).
Furthermore, our finding that even high-dose MTZ, despite complete inhibition of intra-and extracellular CA, did not impair respiratory neuro-mechanical transmission seems rather unexpected in the light of the well-documented role of this enzyme in the regulation of intracellular pH in skeletal muscle (10). However, the efficiency of neuro-mechanical coupling seems to be independent of (CO 2 -induced) pH changes already in the control situation, since V T or tidal ΔP TP and IPNA showed rather sound linear correlations with growing hypercapnia, whereby correlation coefficients in the seven animals ranged from 0.89 to 1.00 or from 0.91 to 0.98, respectively. Likewise, in humans, diaphragmatic contractility remained unaffected by hypercapnic acidosis, in contrast to that of non-respiratory skeletal muscle, e.g. adductor pol-
licis (19).
Although we cannot differentiate between synergistic contributions from the diaphragm and the intercostal muscles (6), we attempted to assess the effect of MTZ on respiratory muscle performance with sufficient accuracy from the relationships between phrenic neural discharge and overall volume/pressure responses to hypercapnia. These relationships showed fair linearity not only under control conditions and upon low-dose MTZ, but also in the majority of animals upon the largest respiratory drive elicited by high-dose MTZ. Thereby, linear correlation coefficients were highest in 6 out of 7 animals (ranging from 0.80 to 0.99), and only in one case the linear compared to the non-linear correlation was smaller (r =0.96 versus 0.98).
Our present data raise the question, by which mechanisms MTZ and the more commonly used There is a uniform non-linear relationship between V T and ΔP TP , representing the dynamic compliance at different levels of respiratory drive before and after application of low-or highdose MTZ. Note that low-dose MTZ does not impair neuro-mechanical transmission, neither in terms of the tidal volume response nor with respect to that of transpulmonary pressure or respiratory work performance. Figure 5 Effects of high-dose methazolamide (MTZ) and acetazolamide (ACTZ) on respiratory work performance.
Neuro-mechanical transmission is expressed as tidal respiratory work (V T ·ΔP TP ) related to the integrated tidal phrenic nerve activity (IPNA). Data are means ± SEM (N=7) obtained at different levels of inhaled CO 2 before and after treatment with high-doses (HD) of either MTZ (this study) or ACTZ from a previous study (15).
At doses sufficient for complete CA inhibition, MTZ does not attenuate neuro-mechanical transmission, whereas ACTZ reduces it by about 50%. 
